In the claims:

For the convenience of the Examiner, all claims being examined, whether or not amended, are presented below.

1-96. **(Canceled)**

97. **(Currently Amended)** A method for decreasing neuronal cell death associated with a neuropathy, comprising contacting said neuronal cell with a morphogen comprising a dimeric protein ~~with~~, the dimeric protein having one or more of the following:

(1) a conserved C-terminal ~~seven~~ six-cysteine skeleton 60% identical to residues ~~38~~ 43-139 of SEQ ID NO: 5;

(2) a conserved C-terminal seven-cysteine skeleton 70% homologous to residues 38-139 of SEQ ID NO: 5;

(3) a conserved C-terminal six-cysteine skeleton 70% homologous to residues 43-139 of SEQ ID NO: 5; or

~~(3)~~(4) an amino acid sequence of human OP-1, mouse OP-1, human OP-2, mouse OP-2, 60A, GDF-1, BMP2A, BMP2B, DPP, Vg1, Vgr-1, BMP3, BMP5, or BMP6~~;~~

~~(4) a sequence defined by Generic Sequence 6, SEQ ID NO: 31; or,~~

~~(5) a sequence defined by OPX, SEQ ID NO: 29~~;

wherein the morphogen stimulates the production of an N-CAM or L1 isoform in said neuronal cell.

98. **(Canceled)**

99. **(Currently Amended)** A method for decreasing neuronal cell death associated with a chemical or physical injury, comprising contacting said neuronal cell with a morphogen comprising a dimeric protein with:

(1) a conserved C-terminal ~~seven~~ six-cysteine skeleton 60% identical to residues ~~38~~ 43-139 of SEQ ID NO: 5;

(2) a conserved C-terminal seven-cysteine skeleton 70% homologous to residues 38-139 of SEQ ID NO: 5;

(3) a conserved C-terminal six-cysteine skeleton 70% homologous to residues 43-139 of SEQ ID NO: 5; or

~~(3)~~(4) an amino acid sequence of human OP-1, mouse OP-1, human OP-2, mouse OP-2, 60A, GDF-1, BMP2A, BMP2B, DPP, Vg1, Vgr-1, BMP3, BMP5, or BMP6~~;~~

~~(4) a sequence defined by Generic Sequence 6, SEQ ID NO: 31; or,~~

~~(5) a sequence defined by OPX, SEQ ID NO: 29~~;

wherein the morphogen stimulates the production of an N-CAM or L1 isoform in said neuronal cell.

100-104.(**Canceled**)

105. (**Previously presented**) The method of claim 97 or 99, wherein the morphogen is human OP-1.

106. (**Previously presented**) The method of claim 97 or 99, wherein the morphogen is mouse OP-1.

107. (**Previously presented**) The method of claim 97 or 99, wherein the morphogen is human OP-1, mouse OP-1, human OP-2, mouse OP-2, 60A, BMP2A, BMP2B, Vg1, Vgr-1, BMP5, or BMP6.

108. (**Previously presented**) The method of claim 97 or 99, wherein the morphogen is human OP-1, mouse OP-1, human OP-2, mouse OP-2, BMP5, or BMP6.

109. (**New**) The method of claim 97 or 99, wherein the morphogen is a dimeric protein having a conserved C-terminal six-cysteine skeleton 60% identical to residues 43-139 of SEQ ID NO: 5.

110. (**New**) The method of claim 97 or 99, wherein the morphogen is a dimeric protein having a conserved C-terminal seven-cysteine skeleton 70% homologous to residues 38-139 of SEQ ID NO: 5.

111. (**New**) The method of claim 97 or 99, wherein the morphogen is a dimeric protein having a conserved C-terminal six-cysteine skeleton 70% homologous to residues 43-139 of SEQ ID NO: 5.